低中危急性髓系白血病患者完全缓解后的治疗

李军民; 张赟翔

doi:10.13201/j.issn.1004-2806.2014.03.002

低中危急性髓系白血病患者完全缓解后的治疗

李军民^,,
张赟翔

- 上海交通大学医学院附属瑞金医院血液科(上海, 200025)

详细信息

作者简介:
李军民,上海市瑞金医院血液科主任,主任医师,上海交通大学医学院博士生导师。现任中华医学会血液学分会委员兼秘书,上海血液学分会副主委,中华医学会内科学分会青年委员。在国内、国际重要学术刊物发表论文50余篇。并承担国家"973"子课题、国家"863"子课题、卫生部行业专项、国家教委骨干教师项目、国家自然科学基金、上海市科委重大项目研究等多项课题。长期从事血液专业的临床医学工作,对血液系统恶性肿瘤和血液免疫疾病治疗具有丰富临床经验。

通讯作者: 李军民,E-mail:lijunmin@medmail.com.cn

中图分类号: R733.71

收稿日期: 2013-11-20

Post-complete remission treatment for acute myeloid leukemia patients in low-or intermediate-risk group

LI Junmin^,,
ZHANG Yunxiang

More Information

Corresponding author: LI Junmin, E-mail: lijunmin@medmail.com.cn

Received Date: 20 November 2013

摘要

- 白血病,髓系,急性 /
- 完全缓解 /
- 治疗
- acute myeloid leukemia /
- complete remission /
- treatment

HTML全文

参考文献(16)

[1]	PULTE D,REDANIEL M T,JANSEN L,et al.Recent trends in survival of adult patients with acute leukemia:overall improvements,but persistent and partly increasing disparity in survival of patients from minority groups[J].Haematologica,2013,98:222-229.
[2]	PATEL J P,GONEN M,FIGUEROA M E,et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J].N Engl J Med,2012,366:1079-1089.
[3]	中华医学会血液学分会.成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南2011[J].中华血液学杂志,2011,32(11):804-807.
[4]	FEY M F,BUSKE C,ESMO Guidelines Working Gr-oup.Acute myeloblastic leukaemias in adult patients:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2013,24 Suppl 6:138-143.
[5]	NCCN.National Comprehensive Cancer Network Gu-idelines-Acute Myeloid Leukemia[J].2013.
[6]	HOURIGAN C S,KARP J E.Minimal residual disease in acute myeloid leukaemia[J].Nat Rev Clin Oncol,2013,10:460-741.
[7]	AL-MAWALI A,GILLIS D,HISSARIA P,et al.Incidence,sensitivity,and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry[J].Am J Clin Pathol,2008,129:934-945.
[8]	TERWIJN M,VAN PUTTEN W L,KELDER A,et al.High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia:data from the HOVON/SAKK AML 42A study[J].J Clin Oncol,2013,31:3889-2897.
[9]	FREEMAN S D,VIRGO P,COUZENS S,et al.Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia[J].J Clin Oncol,2013,31:4123-4131.
[10]	OSSENKOPPELE G,SCHUURHUIS G J.MRD in AML:time for redefinition of CR?[J].Blood,2013,121:2166-2168.
[11]	JOURDAN E,BOISSEL N,CHEVRET S,et al.Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia[J].Blood,2013,121:2213-2223.
[12]	ZHU H H,ZHANG X H,QIN Y Z,et al.MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission:results from the AML05 multicenter trial[J].Blood,2013,121:4056-4062.
[13]	STONE R M.Acute myeloid leukemia in first remis-sion:to choose transplantation or not?[J].J Clin Oncol,2013,31:1262-1266.
[14]	STELLJES M,KRUG U,BEELEN D W,et al.Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia:a prospective matched pairs analysis[J].J Clin Oncol,2014,32:288-296.
[15]	MAWAD R,GOOLEY T A,SANDHU V,et al.Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission[J].J Clin Oncol,2013,31:3883-3888.
[16]	USUKI K,KUROSAWA S,UCHIDA N,et al.Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission[J].Clin lymphoma Myeloma Leuk,2012,12:444-451.